Non-invasive epidermal proteome assessment-based diagnosis and molecular subclassification of psoriasis and eczematous dermatitis

Michael J. Murphy MD[1], Gloria Chen MD[1], Princess Edemobi BS[1], Muhammad H. Junejo MD MsC MRCP(UK)[1], A. Mitchel Wride BS[1], Sarah L. Spaulding BS[1], Yiwei Wang PhD[1], Jeffrey M. Cohen MD[1,2,*], William Damsky MD, PhD[1,3,*]

[1]Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
[2]Section of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, Connecticut, USA.
[3]Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.

*Authors to whom correspondence should be addressed

William Damsky, MD, PhD
Yale School of Medicine, Department of Dermatology
333 Cedar St LCI 501 PO Box 208059
New Haven, CT 06510
Phone: 203-785-4092
Fax: 203-785-7637
E-mail: william.damsky@yale.edu; phone: 203-785-4092

Jeffrey M. Cohen, MD
Yale School of Medicine, Department of Dermatology
333 Cedar St LCI 501 PO Box 208059
New Haven, CT 06510
Phone: 203-785-4092
Fax: 203-785-7637
Email: jeffrey.m.cohen@yale.edu

Funding sources: This work was supported by the Colton Center for Autoimmunity at Yale.

Conflicts of Interest: Yale University (MJM, JMC, WD) has filed a preliminary patent application related to this work. WD is a consultant for Pfizer, Incyte, Eli Lilly, and TWi Biotechnology, has research funding from Pfizer, Advanced Cell Diagnostics/Bio-techne, and AbbVie and receives licensing fees from EMD/Millipore/Sigma, all outside the submitted work. JMC serves on a data and safety monitoring board (DSMB) for Advarra. MJM, GC, PE, AMW, and SLS have no conflicts to disclose.

Manuscript word count: 4658
References: 52
Figures: 5

Abstract

Background:
Immunologic heterogeneity is known to exist within both eczematous dermatitis and psoriasis; however, selection of molecularly targeted therapies for individual patients generally does assess for or incorporate such information about patient-specific immune changes.

Objective:
We sought to develop a rapid, non-invasive method for obtaining and analyzing epidermal protein biomarkers from skin and utilize this methodology to dissect immunologic heterogeneity in both psoriasis and eczematous dermatitis.

Methods: We optimize and evaluate detergent-based immune profiling system (DIPS) which utilizes a combination of two detergents to solubilize full-thickness epidermis when applied to the skin with an applicator. Downstream proteomic profiling of this material allows high-throughput immunologic characterization of immune biomarkers.

Results:
DIPS was performed on 43 patients with psoriasis and 27 patients with eczematous dermatitis. This approach was found to be painless, nonscarring, and enabled rapid turnaround from sample collection to data output. We used this approach to accurately differentiate psoriasis and eczema using a limited set of proteins and to identify cases of eczema/psoriasis overlap with non-canonical molecular profiles. Additionally, we measured patient-specific cytokine profiles in eczema that correlated with response to IL-4Rα blockade.

Conclusion:
DIPS is a promising new non-invasive cutaneous immune profiling approach that can deconvolute immune heterogeneity amongst patients with both psoriasis and eczematous dermatitis.

Clinical Implication:
DIPS has potential applications in both research and day-to-day dermatologic practice and may help personalize diagnosis and medication selection in patients with inflammatory skin diseases.

Capsule summary
Detergent-based immune profiling system (DIPS), a novel non-invasive approach for molecular evaluation of skin disease, is described and evaluated in psoriasis and eczematous dermatitis

Keywords
atopic dermatitis
eczema
eczematous dermatitis
detergent-based immune profiling system
personalized medicine
dupilumab

Abbreviations
BN surfactant: equimolar ratio (0.5% w/v each) of Brij-30 and N-decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate
BSA: body surface area
CCL: CC chemokine ligand
CXCL: C-X-C motif chemokine ligand
DEP: differentially expressed protein
DIPS: detergent-based immune profiling system
IFN: interferon
IGA: Investigator's Global Assessment
IL: interleukin
JAK: Janus kinase
LR: logistic regression
PC: principal component
RFE: recursive feature elimination
TNF: tumor necrosis factor
TYK2: tyrosine kinase 2
UMAP: uniform manifold approximation and projection
vIGA-AD: validated Investigator's Global Assessment for Atopic Dermatitis

Introduction

Psoriasis and eczematous dermatitis (eczema) are among the most common inflammatory skin conditions worldwide (1). Most cases do not require a biopsy for diagnosis, and so tissue is frequently not obtained in patients with these diseases. In some patients, a biopsy is performed to assist with the diagnosis, but may not always provide clarity. Further, cases with overlapping features of psoriasis and eczema have been described (2, 3). Psoriasis and eczema are increasingly treated with molecularly targeted therapies. Approved cytokine targets in psoriasis include TNF, interleukin (IL)-12/23 (p40), IL-23 (p19), IL-17 family, and IL-36. In eczema, approved targets include IL-4 and/or IL-13 (4–6), with others under evaluation. JAK and TYK2 inhibition in eczema and psoriasis, respectively, inhibit groups of cytokines relevant to each disease (7–9).

In clinical practice, it is not uncommon for patients with psoriasis and eczema to have a suboptimal response to one targeted therapy but then an excellent response to another (10–12). Occasionally, there may even be exacerbation of the underlying condition with treatment (13–16). Indeed, prior work suggests that roughly 10-35% of patients with psoriasis and 35-60% of patients with eczema do not achieve clear/almost clear skin with newer therapies (5, 17–19). It has become increasingly apparent that within each diagnosis, there is immunologic heterogeneity, which, at least in part, explains this observation (20–23). For example, while most eczema patients have at least some degree of a Type 2 response (IL-4, IL-13, IL-31), other patients may have concomitant or even predominant Type 1, Type 17, and/or helper T cell (Th)22 responses (23–28). Psoriasis subtypes may also exhibit distinct immunology; for example, in pustular psoriasis, innate immune drivers such as IL-36 appear to be key, while in psoriasis vulgaris the adaptive IL-23/IL-17 axis predominates (24). Even within psoriasis vulgaris immunologic heterogeneity has been described (25).

Assessing the predominant immunologic driver has been shown to be predictive of treatment response or non-response in some instances in patients with these diseases (20, 21, 26). Despite this knowledge, treatment selection in both diseases remains largely empiric, with no ability to dissect the unique immunology of any individual patient in a clinically-feasible fashion to inform therapy selection.

The ideal test for clinically relevant immunologic profiling in the treatment of inflammatory diseases would be easy and quick to obtain, painless and non-scarring, accurate, and have the potential for rapid clinically relevant turnaround. Here, we developed and evaluated detergent-based immune profiling system (DIPS) a noninvasive approach to collect material that could be utilized for downstream proteomic analysis in patients with inflammatory skin disease. We evaluate DIPS in patients with psoriasis and eczema, demonstrating its utility in distinguishing between eczema and psoriasis using immunologic biomarkers. We also explore the utility of the approach to dissect therapeutically relevant intra-disease immunologic heterogeneity; showing the potential of the approach to ultimately help realize the goal of personalized medicine in inflammatory disease.

Methods

Non-invasive epidermal protein biomarker sampling

We utilized a previously described surfactant, herein referred to as BN, consisting of an equimolar ratio (0.5% w/v each) of Brij-30 and N-decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, that, when coupled to dermabrasion, enabled solubilization of the epidermis without breaching of the dermis or scarring (27–29). Skin was swabbed using a microfiber cosmetic applicator and approximately 40μL of surfactant. Swabbing was performed by rubbing the surfactant-coated applicator tip in a back-and-forth motion for 45 seconds, applying light pressure, over a 2mm-by-1mm rectangular area on lesional psoriasis or eczema skin. The tip was then inserted into an Eppendorf tube containing 130μL of phosphate buffered saline and a

protease inhibitor cocktail (Sigma-Adrich #11836153001), let sit for 1 minute, and then rubbed against the interior of the tube to dislodge any attached material. Samples were then immediately placed on wet ice for transport and later were frozen at -80 °C.

High throughput proteomic analysis

Samples were analyzed using the Olink Explore 3072 Panel (Olink Proteomics, Uppsala, Sweden), which provides relative quantification of 3072 proteins related to inflammation and other pathways. This assay utilizes a proximity extension assay (PEA) coupled with a next generation sequencing readout. A subset of samples were also analyzed using the Olink Target 48 Cytokine Panel, which provides absolute quantification of 45 cytokine and chemokine proteins using a PEA-based technique coupled with real-time qPCR readout.

Patient enrollment

Patients were enrolled from a single outpatient dermatology clinic at our tertiary referral center. Criteria for enrollment included age ≥18 years and clinical and/or histologic diagnosis of psoriasis or eczema by a board-certified dermatologist. At least one non-invasive lesional skin sample was obtained per patient, along with demographic information, treatment information, and clinical photographs.

Statistics

Protein quantification data was analyzed using Python v3.8.8 and R v3.6.1. Differentially expressed protein values were computed using the limma v3.42.2 package in R. Machine learning analyses were performed using sci-kit learn v1.1.3 and UMAP was performed using umap-learn v0.5.3 in python. PCA was performed using sci-kit learn v1.1.3 and FactoMineR v2.4 in python and R, respectively. Comparisons between two groups were performed using two-tailed t-tests, and comparisons between multiple groups were performed using ANOVA.

Study Approval

This study was reviewed and approved by the Yale University institutional review board (#2000033233). Written informed consent was received from all patients prior to inclusion in the study. Written informed consent was received for the use of the photographs and the record of informed consent has been retained.

Data availability

Values for all data points and graphs are reported in the Supporting Data Values file. Additional data and supporting code are available from the authors upon request.

Results

Development and evaluation of DIPS for downstream proteomics

Previously, a surfactant consisting of an equimolar ratio of Brij-30 (0.5% w/v) and N-decyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (0.5% w/v) (subsequently referred to as BN surfactant) had been used to extract and measure small numbers of proteins in animal models and has been combined with dermabrasion to extract and measure DNA from human subjects (27–29). We first evaluated the ability of BN surfactant to solubilize human epidermis *ex vivo* when applied and rubbed against the skin with a small applicator. We evaluated six different applicators and selected a microfiber-tipped cosmetic swab due to its superior ability to rapidly solubilize full-thickness epidermis in a small area, easily transfer the specimen to an aqueous solution with minimal volume loss, yield a maximal amount of protein, and result in suitable material for downstream proteomic analysis.

Using this approach on *ex vivo* skin with the microfiber cosmetic swab, we next sought to determine the optimal collection time to reach, but not significantly breach, the dermoepidermal junction (an important consideration that suggests that the approach should be minimally painful and not leave a scar). Post-collection histologic analysis of skin was utilized to evaluate the tissue. We found that a 45 second swab duration resulted in optimal, full thickness epidermal sampling

while generally leaving the dermoepidermal junction intact **(Figure 1A-B**). Periodic acid-Schiff (PAS) staining further demonstrated that the basement membrane remained largely intact **(Figure 1C)**. We found that we were able to use DIPS to collect and transfer epidermal material from a 2x1mm swab area to phosphate buffered saline (PBS) supplemented with protease inhibitors, and detect recombinant IL-13 using the human cytokine/chemokine protein array 71-plex panel (Eve Technologies) after the IL-13 was injected into the superficial dermis and allowed to diffuse for 1 hour at 37°C (**Figure E1**).

Based on our *ex vivo* experiments, we moved forward with BN surfactant, the microfiber cosmetic swab, a 45 second collection duration, and a 2x1 mm collection area with subsequent transfer to PBS supplemented with protease inhibitors. In order to evaluate the utility of DIPS in patients with eczema and psoriasis, we subsequently enrolled 76 patients seen in our outpatient dermatology clinic who underwent DIPS using the developed parameters after informed consent. Patients had a diagnosis of psoriasis (n=43 patients) or eczema (n=27 patients) determined by one of two board-certified dermatologists (JC, WD) using clinical examination and occasionally histopathology when it was deemed clinically necessary to determine the diagnosis. A subset of the cases included non-classical morphologies, allowing us to evaluate the utility of the approach in this setting as well. Healthy control patients (n=6) were also enrolled, and normal skin was sampled.

Clinical severity was assessed using body surface area (BSA) as well as Investigator's Global Assessment (IGA) score and Validated Investor Global Assessment for Atopic Dermatitis (vIGA-AD) score for psoriasis and eczema, respectively (30, 31). BSA was not significantly different between psoriasis and eczema patients (P=0.60), while IGA was higher in the psoriasis group than vIGA-AD in eczema (P=0.0032). Additional patient information is available in **Table E1**.

We found that DIPS was very well tolerated. Patients reported either no or, at most, minimal discomfort during sample collection. The swabbing procedure resulted in a depressed

erosion after the collection was complete **(Figure 1D)**. We found that the sampled skin rapidly re-epithelized, and at 3-month follow-up there was no significant scarring or pigmentary alteration (**Figure 1E**), even in patients with darker skin tones (data not shown).

DIPS enables detection of differentially expressed immunologically-relevant proteins in psoriasis and eczema

Samples collected using DIPS were stored at -80°C until analysis. These samples were subsequently subjected to affinity-based proteomic analysis using a proximity extension assay (PEA)-based approach (Olink Explore 3072). Olink was selected due to its high specificity, requiring binding of two distinct antibodies to each target for signal detection. The Explore 3072 panel provides quantitative measurement of >3000 proteins, including numerous cytokines and chemokines (**Figure 1F**).

First, we asked if the approach was able to detect immunologic differences characteristic of psoriasis and eczema as a whole. Individual protein concentrations were not normalized to the median protein concentration within each sample in order to preserve relative protein concentrations between samples and the observation that similar results were obtained with or without normalization. We computed log base 2-fold change for each measured protein and compared between psoriasis and eczema patients; adjusted p-values were calculated to evaluate significance. Many of the most significantly differentially expressed proteins (DEPs) were related classical immune polarization pathways, including Type 3 (IL-17A and IL-17F) and Type 1 (IFN-γ, IL-12, IL-12p40, CXCL9, CXCL10, and CXCL11) polarized responses in psoriasis, and a Type 2 (IL-4, CCL2, CCL13, CCL17, CCL18, CCL19, and CCL22) polarized response in eczema. Several innate immune mediators were also upregulated in psoriasis including IL-36A and IL17-C. Previously described psoriasis biomarkers were also upregulated in psoriasis including NOS2, NT5C3A, GBP1, PI3 and TMPRSS11D, while eczema demonstrated significant upregulation of

previously described biomarkers including MMP7, MMP10, ITGAX, and EGF, among others (**Figure 2A**).

Upstream regulator analysis was then performed on the DEPs in order to infer key signaling molecules leading to the observed DEP patterns. We found that in the psoriasis cases, some of the most significant predicted upstream regulators were IL-17A and IL-23 (Type 3), IFN-γ, IL-12, IL-15, and STAT1 (Type 1), TNF, NF-κβ, and IL-36. In eczema, they were IL-13 (Th2), IL-10, and CCL2 (**Figure 2B**). IRF4, which can drive dendritic cells to polarize T cells towards Th2, was also upregulated in eczema (32, 33). These patterns were conserved independent of the individual DIPS sample collector (data not shown).

We were surprised that while IL-13 was a highly significant upstream regulator in eczema, its differential expression between psoriasis and eczema was minimal. Given that IL-13 is an important mediator of and key treatment target in eczema, we wondered if a technical limitation in IL-13 detection may have been responsible for its low differential expression in the Olink Explore 3072 panel. To investigate this, we analyzed a subset of our samples (eczema = 14, psoriasis = 20, control = 2) using the Olink Target 48 Cytokine Panel, which utilizes real-time quantitative polymerase chain reaction (qPCR) readout of antibody barcodes for absolute protein quantification of a smaller subset of 45 cytokine/chemokine proteins, rather than a next generation sequencing (NGS)-based readout for relative quantification of 3072 proteins as does the Explore assay.

Using the Target 48 Cytokine Panel, we found that IL-13 was significantly upregulated in eczema (mean ± standard deviation; 3.5±5.3 pg/μL) compared to psoriasis (0.16±0.17, $P<0.01$) and controls (0.12±0.01). Other targets identified using the Explore 3072 panel showed expected differences between psoriasis and eczema (**Figure 2C**). Additionally, while other canonical cytokines such as IL-17A were generally well correlated between the Explore 3072 and Target 48 assays (Pearson correlation coefficient (PCC) = 0.93), IL-13 was less well correlated (PCC = 0.74) (**Figure E2**). Bland-Altman analysis of IL-13, which evaluates the difference in measured

values between the two assays as a function of the mean of both values, demonstrated that the bias changed directionality for high versus low IL-13 values, which was not the case for other cytokines such as IL-17A. Thus, the less accurate detection of IL-13 in the Explore 3072 panel may reflect difficulty in detecting IL-13 in cases with relatively lower concentrations of IL-13 (**Figure E3**).

Distinct protein signatures differentiate psoriasis from eczema

We then sought to determine whether psoriasis and eczema patients could be accurately discriminated using relative protein abundances measured with this approach. We performed principal component analysis (PCA) of the top 10 DEPs in both psoriasis and eczema (20 DEPs total), which resulted in relatively distinct clustering of eczema and psoriasis with minimal admixing (**Figure 2D**). To quantify the extent of overlap, we performed unsupervised Gaussian mixture modeling on principal components (PC) 1 and 2, which optimally identified two clusters. Cluster 1 contained 88.6% of psoriasis samples (39/44) while cluster 2 contained 96.8% of eczema samples (30/31) (**Figure 2E** and **Figure E4**).

We then investigated which protein biomarkers were most representative of each PC and found that NOS2 was most positively correlated with PC1 while CCL17 and CCL19 were most positively correlated with PC2 (**Figure 2F**). We also performed similar analyses using all measured proteins as well as all cytokines/chemokines (**Figure E5**). We found considerable overlap using all measured proteins, highlighting similarities in the overall proteome between the two diseases; in contrast, when only cytokines/chemokines were used, the result was comparable to that of the top 20 DEPs in accordance with the distinct immunology of the two conditions.

As an alternative form of dimensionality reduction, we also performed uniform manifold approximation and projection (UMAP) using the top 10 DEPs for each condition. This resulted in two spatially distinct clusters, one containing the majority of psoriasis (38/44, 86.4%) and the other containing the majority of eczema samples (30/31, 96.8%) (**Figure E6**). Notably, all overlapped

samples in the PCA analysis were also identified as overlapped in the UMAP analysis, suggesting to us that unique underlying proteomic changes might account for the clustering patterns observed in these samples, as opposed to a limitation in accuracy.

Given the close association of NOS2 and CCL17 with PC1 and PC2 from the PCA analysis, we inquired whether these two biomarkers alone would enable discrimination between psoriasis and eczema. Indeed, we found that this analysis yielded similar results to the PCA analysis; one majority psoriasis cluster (38/39, 97%) and one majority eczema cluster (30/36, 83%) emerged. A single eczema sample with elevated NOS2 and 6 psoriasis samples with low NOS2 overlapped between the clusters (**Figure E7).** These were the same overlapping samples identified in the PCA and UMAP analyses, indicating that low NOS2 expression was a hallmark of the psoriasis subset that proteomically clustered with eczema, and high NOS2 expression characterized the eczema sample that clustered with psoriasis.

Lastly, we trained and tested a logistic regression (LR) machine learning classifier to identify a set of protein biomarkers that enabled optimal classification of psoriasis and eczema samples. All measured protein values were first standardized by removing the mean and scaling to unit variance, and then recursive feature elimination (RFE) was used to select a subset of proteins that resulted in the best accuracy. The LR classifier identified a minimum set of 5 proteins (PI3, IL-12B, CCL17, CCL2, CXCL13) that led to 100% accurate discrimination between psoriasis and eczema (**Figure E8**). Interestingly, when the NOS2-low psoriasis and NOS2-high eczema patients were removed from the analysis, an LR classifier could be trained using only NOS2 and CCL17 that enabled 100% accurate diagnosis of psoriasis and eczema. Taken together, these findings implied to us that these “outlier” cases are biologically unique with non-canonical immunology as opposed to an error in the clustering approach. These findings are compatible with previously described eczema and psoriasis immunology, including cases with overlapping features (34).

Analysis of psoriasis samples reveals immunologic heterogeneity and distinct NOS2 high and low subtypes

Next, we sought to better understand differences between the low NOS2 (n=6) and high NOS2 (n=38) psoriasis samples. Clinically, there was no significant difference in BSA involvement between the NOS2-low and NOS2-high cohorts (P=0.57) although the IGA was significantly lower in the NOS2-low cohort (P=0.026) **(Figure 3A**). Histologically, those cases that were biopsied from the NOS2-low demonstrated histologic features of psoriasis (regular acanthosis, confluent parakeratosis, diminution of the granular cell layer, and dilated, tortuous vessels in the dermal papillae) but also showed superimposed changes of eczema-like histology, including focal spongiosis and serum, supporting an overlap phenotype (**Figure 3A**).

We then examined DEPs between the two groups. We found that in addition to NOS2, many of the most significant DEPs in the NOS2-high group related to classic psoriasis immunology and included IL-17A and IL-17F (Th17), IL-12 and IL-12p40 (Th1), IL-17C, IL-36A, CXCL1, CXCL8, and CCL20 **(Figure 3B)**. Interestingly, several proteins classically associated with eczema, including IL-4, CCL17, and CCL22, were differentially upregulated in the low NOS2 group, again supporting the notion of overlapping immunologic features with eczema.

To identify a minimum subset of immunologic proteins that could distinguish the NOS2-high and NOS2-low cohorts, we trained and tested an LR classifier on all cytokines and chemokines. Protein values were standardized, and RFE was used to select a subset of proteins that resulted in the best accuracy. This process identified IL-17A and CCL17 as a minimum set of proteins that enabled prediction of low NOS2 versus high NOS2 cases with 100% accuracy by the LR classifier (**Figure 3C**). IL-17A was downregulated and CCL17 was upregulated in the NOS2-low cases. Together, these findings explain the initial clustering of the NOS2-low psoriasis cases more closely to eczema compared other psoriasis cases (**Figure 2D**).

To further explore immunologic heterogeneity within psoriasis, we created heatmaps using hierarchical unsupervised clustering of all cytokines and chemokines (**Figure 3D-3E**). The low

NOS2 psoriasis cases were generally found to have cytokine/chemokine profiles that were more similar to healthy controls than were the profiles of high NOS2 psoriasis cases. Interestingly, 3 out of 4 psoriasis samples with the highest mean cytokine and chemokine protein values were obtained from patients with new onset guttate psoriasis secondary to group A strep infection and were the only such patients in this study (A200, A201, and A207). Treatment relevant cytokines, such as IL17-A, IL-17F, IL-12B, IFN-γ, and IL-36A, also tended to be lower in the low NOS2 cases compared to high NOS2 cases; however, these differences were only significant in IL17-A, IL-17F, and IL-12B (**Figure 4**). Further, significant intra-patient variability in cytokine/chemokine profiles within each group was apparent, particularly for IL-17F and IFN-γ. Given that each of these cytokines is targeted by distinct therapies, these differences may have implications for treatment response. Such variability was present in other cytokines as well (**Figure E9**).

Non-canonical eczema immunology is associated with non-response to IL-4/IL-13 blockade

Many cases of eczema are driven predominantly by IL-13 and are effectively treated with IL-4Rα blockade or IL-13 blockade. Other cases may have more cytokine driver diversity and may be better suited for treatment with a JAK inhibitor or other approaches. Presently, there is no clinically relevant way to distinguish between the two groups other than therapeutic trial and error. To explore protein heterogeneity in eczema and its implications for therapeutic response, we utilized several unsupervised and supervised machine learning approaches to analyze our dataset.

First, we performed unsupervised hierarchical clustering using all ILs (**Figure 5A**). This analysis identified two overarching distinct clusters; cluster 1 contained samples that were relatively more inflamed with elevated levels of multiple cytokines, while cluster 2 samples tended to be relatively less inflamed. The samples in cluster 1 were A34, A96, A105, A114, A126/127 (both from the same patient), A204, and A220. Of these, patients A105, A126/127, and A204 had

moderate-to-severe disease and were initiated on dupilumab. Interestingly, each of these patients failed to respond or worsened on dupilumab as measured by BSA involvement and vIGA-AD score after approximately 3 months. One patient (A126/127) was subsequently initiated on a JAK1 inhibitor with improvement. Also of note, patient A114 was treated with the IL-13 blocker tralokinumab with minimal response and was also subsequently successfully treated with a JAK1 inhibitor. The remainder of samples in Cluster 1 did not receive systemic therapy. These results suggest that certain patterns of cytokine expression, such as those identified in cluster 1, may correlate with response to therapy.

Next, we performed PCA using all measured proteins (**Figure 5B**). This analysis identified a central cluster with several outlier cases. The main cluster contained all patients who were responders to dupilumab (A76 and A89/116). Patients who were proteomic outliers included A34, A96, A105, A126/127, A204, and A220, all of which were contained in cluster 1 in the prior analysis, suggesting that outlier overall protein profiles also may correlate with nonresponse to therapy.

After utilizing the unsupervised learning approaches above, we then sought to use supervised learning approaches to determine whether a limited set of immune protein biomarkers could accurately predict non-response to IL-4/IL-13 blockade. In our entire dataset, we identified 3 samples from 2 patients who responded to IL-13 blockade and 10 samples from 7 patients who did not after 3-month follow-up. Notably, all of the non-responders had biopsies performed. The predominant histologic finding in all cases was spongiotic dermatitis without evidence of cutaneous T-cell lymphoma, interface dermatitis, or other processes. There was no significant difference in BSA or IGA between responders and non-responders (**Figure E10**).

We then trained and tested an LR classifier on all cytokines and chemokines; protein values were standardized, and RFE was used to select a subset of proteins that resulted in the best accuracy. We found that 4 proteins, CXCL9, CXCL14, IFN-γ, and IL-9, enabled 100% accurate classification of responders and non-responders (**Figure 5C**). Heatmaps of these

proteins are shown in **Figure 5E**. To us, this also made intuitive sense in that IFN-γ (and downstream target CXCL9) reflect activated Type 1 immunity, which is inhibited by JAK inhibition but not IL-4/IL-13 blockade. IL-9 is a common gamma chain cytokine relying on JAK-STAT signaling to exert its effect and similarly is inhibited by JAK inhibition but not dupilumab.

Discussion:

In this study, we optimized and evaluated the ability of DIPS and downstream proteomic analysis to sample and subclassify eczema and psoriasis using immunologic biomarkers. This approach was found to be painless, nonscarring, and could enable rapid turnaround from time of sample collection to data output. We also used this approach to accurately differentiate psoriasis and eczema using a limited set of proteins and to identify cases of eczema/psoriasis overlap with non-canonical molecular profiles. Further, we measured patient-specific cytokine profiles in eczema that correlated with response to targeted therapy.

Prior attempts to evaluate immunologic heterogeneity in psoriasis and eczema have largely relied on mRNA sequencing from skin biopsies, tape strips, and/or skin scrapings (curettage) (20, 25, 34–36). While these approaches have provided significant insight into psoriasis and eczema pathobiology and heterogeneity, they have several limitations. Tape stripping, for example, can be time consuming and mostly samples the cornified layer and not the underlying epidermis. Curettage is likely highly user-dependent and may not ensure consistent sampling depth. Further, mRNA is unstable and requires specialized collection approaches. Analysis of mRNA with RNA-sequencing is labor intensive, requires specialized equipment, expertise, and data normalization, and may miss changes occurring at the post-transcriptional level, which is important for many diagnostically and therapeutically relevant cytokines including TNF, IL-36, and IL-1β.

While proteomic profiles have been evaluated in blood of patients with atopic dermatitis (37–39), they may be limited in utility for inflammatory skin disease due to high inter-individual variability and impact of renal function on biomarker levels. Proteomic profiling of skin-derived samples in psoriasis and eczema has also been performed previously (40–42) but predominantly relied on tape stripping for sample collection which may not accurately capture signal concentrated in the basal and spinous layers of the epidermis. We believe that in general, DIPS, which reproducibly samples full-thickness epidermis, provides distinct advantages over existing approaches in terms of non-invasive sample collection.

We found that clinical diagnosis of psoriasis and eczema could be accurately distinguished using a limited set of biomarkers that overlapped with previously identified biomarkers in both diseases (43–46). Interestingly, we identified several cases that were clinically and/or histopathologically diagnosed as psoriasis but showed molecular overlap with eczema and one case of eczema that showed molecular overlap with psoriasis. Lower NOS2 and IL-17A were hallmarks of psoriasis cases with overlapping eczema immunology, while the eczema case with overlapping psoriasis immunology showed higher NOS2 and IL-17A. This is compatible with the increasing recognition that some cases of psoriasis and eczema may show overlapping features between the two diseases. For example, a prior study sought to characterize the mRNA profiles of clinically identified psoriasis-eczema overlap patients and identified several patients with low *NOS2*, *IL17A*, and/or *IL17F*, consistent with our findings (34). In clinical practice, these cases can be some of the most challenging to treat, underscoring the need to incorporate disease biomarker assessment into therapeutic selection.

Consistent with prior work, the degree of molecular heterogeneity appeared to be greater in eczema (47). Our results extend these findings and suggest that this molecular heterogeneity may correlate with response to IL-13 blocking therapies. We identified a specific subset of proteins (IFN-γ, IL-9, CXCL9, and CXCL14) that correlated with whether a patient responded to IL-4/IL-13

inhibition. Prior analysis of mRNA expression in skin biopsies identified elevated *IFNG* as a predictor non-response to dupilumab, which is consistent with our findings (20, 21).

The approach described herein may have potential uses beyond the scope of this study. Given that it represents a general platform for skin protein collection and analysis, it may be useful for studying other inflammatory skin diseases beyond psoriasis and eczema. Further, it may offer a relatively straightforward method for identifying and collecting biomarkers to guide clinical trial enrollment, for example, identifying atopic dermatitis patients with high IL-22 expression that respond optimally to IL-22 targeted therapies (26). Lastly, it may be useful in identifying diseases or subsets of patients that may benefit from existing therapies that are not FDA approved for those indications, yet strongly express treatment targets of those medications.

Our results must be considered in the context of several limitations. First, the inability to accurately measure IL-13 at low concentrations impeded our ability to detect inter and intra-disease differences in its levels; this is significant given that IL-13 is known to be differentially expressed between eczema and psoriasis and may be an important predictor of response to IL-13 blockade (20, 21, 47). We were able to overcome this by using an alternate proteomic readout for IL-13 that showed superior accuracy and will be a cornerstone of future evaluation of this approach. Additionally, the Olink panels utilized do not detect IL-23, which is known to be an important disease mediator and treatment target in psoriasis (48). Therefore, our results may not fully capture all relevant proteins in these disease processes and may be limited in this regard. Furthermore, our study did not include psoriasis phenotypic variants aside from plaque and acute guttate psoriasis. Pustular psoriasis, for example, will be important to include in the future and may show a greater degree of innate immune activation. Psoriasis and eczema of special sites, such as acral disease, may have distinct immunology and will also be important to include in future studies (49–52). Lastly, our analysis of IL-13 blockade responders and nonresponders was limited by small sample size and over-representation of dupilumab nonresponders; it will be important to validate these findings in a larger cohort with extended follow-up.

Acknowledgements:

The authors thank K. Tsai for supplying the NB surfactant for initial evaluation of this approach. This publication was made possible by the Yale School of Medicine Fellowship for Medical Student Research and The Richard K. Gershon, M.D., Endowed Medical Student Research Fellowship (MJM). AMW and SLS were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35DK104689. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. *J Invest Dermatol*. 2014;134(6):1527-1534. doi:10.1038/jid.2013.446

2. Cohen JN, Bowman S, Laszik ZG, North JP. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis. *J Am Acad Dermatol*. 2020;82(2):430-439. doi:10.1016/j.jaad.2019.08.023

3. Noorily AR, Criscito MC, Cohen JM, Brinster NK. Psoriasis With Eczematous Features: A Retrospective Clinicopathologic Study. *Am J Dermatopathol*. 2021;43(2):112-118. doi:10.1097/DAD.0000000000001711

4. Kim J, Krueger JG. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. *Annu Rev Med*. 2017;68:255-269. doi:10.1146/annurev-med-042915-103905

5. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med*. 2016;375(24):2335-2348. doi:10.1056/NEJMoa1610020

6. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). *Br J Dermatol*. 2021;184(3):437-449. doi:10.1111/bjd.19574

7. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. *N Engl J Med*. 2021;384(12):1101-1112. doi:10.1056/NEJMoa2019380

8. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet*. 2021;397(10290):2151-2168. doi:10.1016/S0140-6736(21)00588-2

9. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. *J Am Acad Dermatol*. 2023;88(1):29-39. doi:10.1016/j.jaad.2022.07.002

10. Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). *J Am Acad Dermatol*. 2022;87(2):351-358. doi:10.1016/j.jaad.2022.04.009

11. Hu Y, Chen Z, Gong Y, Shi Y. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. *Clin Drug Investig*. 2018;38(3):191-199. doi:10.1007/s40261-017-0603-3

12. Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. *Br J Dermatol*. 2021;184(1):50-59. doi:10.1111/bjd.19341

13. Ungar B, Pavel AB, Li R, et al. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. *J Allergy Clin Immunol*. 2021;147(1):394-397. doi:10.1016/j.jaci.2020.04.055

14. Trave I, Salvi I, Burlando M, Cozzani E, Parodi A. “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature. *J Clin Med*. 2023;12(19):6291. doi:10.3390/jcm12196291

15. Su Z, Zeng YP. Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review. *Dermatology*. 2023;239(4):646-657. doi:10.1159/000530608

16. Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. *J Am Acad Dermatol*. Published online December 8, 2020:S0190-9622(20)33154-6. doi:10.1016/j.jaad.2020.12.010

17. Ruggiero A, Megna M, Fabbrocini G, Ocampo-Garza SS. Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. *Immunol Res*. 2023;71(3):328-355. doi:10.1007/s12026-022-09356-y

18. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. *N Engl J Med*. 2014;371(4):326-338. doi:10.1056/NEJMoa1314258

19. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. *JAMA Dermatol*. 2022;158(4):404-413. doi:10.1001/jamadermatol.2022.0029

20. Singh K, Valido K, Swallow M, et al. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. *J Am Acad Dermatol*. 2023;88(5):1094-1100. doi:10.1016/j.jaad.2022.12.052

21. Murphy MJ, Hwang E, Singh K, Lee T, Cohen JM, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. *Br J Dermatol*. 2023;190(1):132-134. doi:10.1093/bjd/ljad389

22. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? *Curr Opin Immunol*. 2017;48:68-73. doi:10.1016/j.coi.2017.08.008

23. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. *J Allergy Clin Immunol*. 2019;143(1):1-11. doi:10.1016/j.jaci.2018.10.032

24. Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. *Am J Clin Dermatol*. 2022;23(Suppl 1):13-19. doi:10.1007/s40257-021-00655-y

25. Wang A, Fogel AL, Murphy MJ, et al. Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis. *JID Innov*. 2021;1(2):100021. doi:10.1016/j.xjidi.2021.100021

26. Brunner PM, Pavel AB, Khattri S, et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. *J Allergy Clin Immunol*. 2019;143(1):142-154. doi:10.1016/j.jaci.2018.07.028

27. Hwang BH, Doshi N, Tsai KY, Mitragotri S. A reagent to facilitate protein recovery from cells and tissues. *Drug Deliv Transl Res*. 2012;2(5):297-304. doi:10.1007/s13346-012-0071-5

28. Hwang BH, Tsai KY, Mitragotri S. Optimized lysis buffer reagents for solubilization and preservation of proteins from cells and tissues. *Drug Deliv Transl Res*. 2013;3(5):428-436. doi:10.1007/s13346-013-0128-0

29. Muradova E, Patel N, Sell B, et al. Noninvasive Assessment of Epidermal Genomic Markers of UV Exposure in Skin. *J Invest Dermatol*. 2021;141(1):124-131.e2. doi:10.1016/j.jid.2020.05.093

30. Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. *J Dermatolog Treat*. 2015;26(1):23-31. doi:10.3109/09546634.2013.865009

31. Simpson E, Bissonnette R, Eichenfield LF, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. *J Am Acad Dermatol*. 2020;83(3):839-846. doi:10.1016/j.jaad.2020.04.104

32. Williams JW, Tjota MY, Clay BS, et al. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. *Nat Commun*. 2013;4:2990. doi:10.1038/ncomms3990

33. Gao Y, Nish SA, Jiang R, et al. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. *Immunity*. 2013;39(4):722-732. doi:10.1016/j.immuni.2013.08.028

34. Kim JE, Lee J, Huh YJ, et al. Genomic Profiling of the Overlap Phenotype between Psoriasis and Atopic Dermatitis. *J Invest Dermatol*. 2024;144(1):43-52.e6. doi:10.1016/j.jid.2023.06.194

35. Fischer F, Doll A, Uereyener D, et al. Gene Expression-Based Molecular Test as Diagnostic Aid for the Differential Diagnosis of Psoriasis and Eczema in Formalin-Fixed and Paraffin-Embedded Tissue, Microbiopsies, and Tape Strips. *J Invest Dermatol*. 2023;143(8):1461-1469.e5. doi:10.1016/j.jid.2023.02.015

36. Barber C, Boiko S. Tape stripping: investigational, diagnostic, and therapeutic uses in dermatology. *Clin Dermatol*. 2022;40(4):355-362. doi:10.1016/j.clindermatol.2022.02.008

37. Navrazhina K, Garcet S, Frew JW, et al. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. *J Am Acad Dermatol*. 2022;86(2):322-330. doi:10.1016/j.jaad.2021.07.035

38. Song B, Wu C, Liu W, et al. Integrative serum proteomics analysis reveals distinct immune and cardiovascular profile dysregulation in erythrodermic psoriasis. *Br J Dermatol*. 2023;189(6):769-771. doi:10.1093/bjd/ljad283

39. Al-Janabi A, Martin P, Khan AR, et al. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics. *J Allergy Clin Immunol*. 2023;152(5):1237-1246. doi:10.1016/j.jaci.2023.07.011

40. Sobolev VV, Soboleva AG, Denisova EV, et al. Proteomic Studies of Psoriasis. *Biomedicines*. 2022;10(3):619. doi:10.3390/biomedicines10030619

41. Méhul B, Laffet G, Séraïdaris A, et al. Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling. *Br J Dermatol*. 2017;177(2):470-488. doi:10.1111/bjd.15346

42. Méhul B, Ménigot C, Fogel P, et al. Proteomic analysis of stratum corneum in Cutaneous T-Cell Lymphomas and psoriasis. *Exp Dermatol*. 2019;28(3):317-321. doi:10.1111/exd.13880

43. Deng J, Leijten E, Zhu Y, et al. Multi-omics approach identifies PI3 as a biomarker for disease severity and hyper-keratinization in psoriasis. *J Dermatol Sci*. 2023;111(3):101-108. doi:10.1016/j.jdermsci.2023.07.005

44. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. *J Invest Dermatol*. 1998;111(6):1053-1057. doi:10.1046/j.1523-1747.1998.00446.x

45. Liu J, Chang HW, Huang ZM, et al. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. *J Allergy Clin Immunol*. 2021;147(6):2370-2380. doi:10.1016/j.jaci.2020.11.028

46. Del Duca E, Renert-Yuval Y, Pavel AB, et al. Proteomic characterization of atopic dermatitis blood from infancy to adulthood. *J Am Acad Dermatol*. 2023;88(5):1083-1093. doi:10.1016/j.jaad.2022.12.050

47. Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. *J Invest Dermatol*. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018

48. Yang K, Oak ASW, Elewski BE. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. *Am J Clin Dermatol*. 2021;22(2):173-192. doi:10.1007/s40257-020-00578-0

49. Chen JS, Murphy MJ, Singh K, et al. IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies. *JID Innov*. 2023;3(4):100189. doi:10.1016/j.xjidi.2023.100189

50. Bissonnette R, Suárez-Fariñas M, Li X, et al. Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. *PLoS One*. 2016;11(5):e0155215. doi:10.1371/journal.pone.0155215

51. Ahn R, Yan D, Chang HW, et al. RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways. *Sci Rep*. 2018;8(1):11368. doi:10.1038/s41598-018-29472-w

52. Carlén LM, Sánchez F, Bergman AC, et al. Proteome analysis of skin distinguishes acute guttate from chronic plaque psoriasis. *J Invest Dermatol*. 2005;124(1):63-69. doi:10.1111/j.0022-202X.2004.23501.x



Figure 1. Histologic and clinical overview of DIPS. (A) H&E stain showing sampled and non-sampled epidermis (arrow denotes transition point, 40X), (B) H&E stain (arrow denotes transition point, 200X), (C) PAS stain (arrow denotes transition point, 200X), (D) representative images of a psoriasis lesion before and after DIPS, (E) clinical course of healthy control skin after DIPS, (F) overview of our approach utilizing DIPS and downstream proteomics. *H&E*, hematoxylin & eosin; *PAS*, periodic acid-Schiff.



Figure 2. Comparison of the proteomes of psoriasis and eczema. (A) Volcano plot of differentially expressed proteins between psoriasis and eczema measured using Explore 3072, (B) volcano plot of differential upstream regulator proteins between psoriasis and eczema determined via pathway analysis, (C) volcano plot of differentially expressed proteins between psoriasis and eczema measured using Target 48, (D) scatterplot of psoriasis and eczema samples on PC1 and PC2 after PCA using the top 10 DEPs in each diagnosis, (E) composition of clusters identified via gaussian mixtures modeling performed on PC1 and PC2 (F) biplot derived from PCA using the top 10 DEPs in psoriasis and eczema.
LogFC, log base 2 fold-change; *-Log(FDR)*, negative log base 10 of false discovery rate; *PC*, principal component; *PCA*, principal component analysis; *DEP*, differentially expressed protein.



Figure 3. Evaluation of immunologic heterogeneity in psoriasis samples. (A) Representative clinical and H&E histological images from low NOS2 psoriasis patients (40X), (B) Volcano plot of differentially expressed proteins between low NOS2 and high NOS2 psoriasis patients, (C) scatterplot of LR classification of low NOS2 and high NOS2 psoriasis on PC1 and PC2 after PCA using NOS2 and CCL17, (D) heatmap of all measured cytokines after hierarchical unsupervised clustering, (E) heatmap of all measured chemokines after hierarchical unsupervised clustering.
LogFC, log base 2 fold-change; *-LogFDR*, negative log base 10 of false discovery rate; *LR*, logistic regression; *PC*, principal component; *PCA*, principal component analysis; *GT*, guttate.



Figure 4. Differences in treatment relevant cytokines and select chemokines between NOS2 low and high psoriasis. (A) Boxplots of treatment relevant cytokines and select chemokines. * P<0.05, ** P<0.01, *** P<0.001, N.S. not significant.
Cont, Control; *lowNOS2*, low NOS2 psoriasis; *PsO*, psoriasis.



Figure 5. Evaluation of immunologic heterogeneity in eczema samples and correlation with response to therapy. (A) Heatmap of all measured cytokines after hierarchical unsupervised clustering (responder samples highlighted in blue, non-responders in red), (B) scatterplot of all eczema samples on PC1 and PC2 after PCA using all measured proteins, (C) scatterplot of LR classification of responders vs non-responders to IL-13 blockade on PC1 and PC2 after PCA using CXCL9, CXCL14, IFN-γ, and IL-9, (D) heatmap of CXCL9, CXCL14, IFN-γ, and IL-9 in responders and non-responders after hierarchical unsupervised clustering. *PC*, principal component; *GT*, guttate.